International Journal of Cardiovascular Research & Innovation

ABSTRACT

Cardiac remodeling is a dynamic and progressive process characterized by structural and molecular alterations in the myocardium, often occurring silently in the early stages of hypertension. Early detection remains a major clinical challenge, as conventional imaging and biochemical markers typically identify changes only after significant damage has occurred. Emerging evidence from molecular cardiology highlights circulating microRNAs (miRNAs), notably miR-21, associated with myocardial fibrosis, and miR-133a, linked to cardiomyocyte hypertrophy, as promising early biomarkers of subclinical cardiac remodeling. This short communication presents findings from a focused observational study evaluating plasma levels of these miRNAs in pre-hypertensive individuals. Results demonstrated a consistent trend of elevated miR-21 and suppressed miR-133a expression compared to normotensive controls, suggesting early molecular shifts in cardiac homeostasis. These findings underscore the potential for integrating microRNA-based diagnostics into routine screening, offering a novel, non-invasive tool for personalized risk assessment and early intervention in cardiovascular care.

Article History

Received 6 December 2024; Revised 20 December 2024; Accepted 27 December 2024

KEYWORDS

1. Cardiac remodeling
2. microRNAs (miRNAs)
3. miR-21
4. miR-133a
5. Pre-hypertension